| Bioactivity | GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.1. GSK2646264 also inhibits other kinases with pIC50 values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin[1]. |
| Invitro | GSK2646264 (0.01-10 μM; 1 h) significantly inhibits anti‐IgE (but not C5a)‐induced histamine release from skin mast cells in a concentration‐dependent manner. The IC50 is 0.7 μM and the IC90 is 6.8 μM[2].GSK2646264 cream (0.5, 1, and 3% [wt/wt]; 1 cm2; 4 and 24 h) inhibits anti‐IgE‐induced histamine release from mast cells in ex vivo human skin[2]. |
| Name | GSK2646264 |
| CAS | 1398695-47-0 |
| Formula | C24H26N2O2 |
| Molar Mass | 374.48 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Barker MD, et al. Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease. Bioorg Med Chem Lett. 2018 Nov 15;28(21):3458-3462. [2]. Ramirez Molina C, et al. GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin. Br J Pharmacol. 2019 Apr;176(8):1135-1142. |